Dear Label_Name,

Greetings! I hope you are well.

I am writing on behalf of an international publishing house, Science and Education Publishing, USA (http://www.sciepub.com).

Science and Education Publishing (SciEP) is a multidisciplinary open access publisher of Journals covering the fields of Science, Technology and Medicine. All SciEP publications are subject to high-quality peer review, editorial and production processes and are freely available online.

Welcome to the April, 2013 edition of SciEP newsletter, providing monthly summaries of articles on science & education related topics of interest to scientist and professionals. The mission of our journals is to provide an open access forum for publishing new findings on issues pertinent to scientific and academic field. We also invite you to submit original research papers, review articles, short reports, or case studies are considered for publication in our Multidisciplinary Journals.

American Journal of Public Health Research
DOI: 10.12691/ajphr-1-1-3

The Implementation of a Tele-Homecare System with Service Oriented Architecture and HL7 Message Transmission Standard
Ching-Sung Wang

American Journal of Medical and Biological Research
DOI: 10.12691/ajmbr-1-1-2

The Influence of Ethanol on Pyruvate Kinases Activity in Vivo, in Vitro, in Silico
Lelevich Sergey Vladimirovich, Khrustalev Vladislav Victorovich, Barkovsky Eugene Victorovich, Shedogubova Tatyana Aleksandrovna

American Journal of Medical Sciences and Medicine
DOI: 10.12691/ajmsm-1-1-1

Clinical and Histological Features in Wegener Granulomatosis
Li Cavoli Gioacchino, Passantino Rita, Bono Luisa, Tortorici Calogera, Ferrantelli Angelo, Giammarresi Carlo, Rotolo Ugo

American Journal of Infectious Diseases and Microbiology
DOI: 10.12691/ajidm-1-1-2

The Curse of Lymphatic Filariasis: Would the Continual Use of Diethylcarbamazine Eliminate this Scourge in Papua New Guinea?
Anne Lanham, Lillian Mwanri

We have released issues of some journals on February 2013.
American Journal of Public Health Research
American Journal of Medical Sciences and Medicine
American Journal of Medical and Biological Research
American Journal of Pharmacological Sciences
American Journal of Clinical Medicine Research
American Journal of Nursing Research
American Journal of Cancer Prevention
American Journal of Medicine Studies
American Journal of Infectious Diseases and Microbiology
American Journal of Cardiovascular Disease Research
American Journal of Biomedical Research
American Journal of Mechanical Engineering
American Journal of Microbiological Research
Journal of Preventive Medicine
American Journal of Food and Nutrition
American Journal of Hypertension Research
American Journal of Sports Science and Medicine
Journal of Cancer Research and Treatment
American Journal of Zoological Research
Journal of Biomedical Engineering and Technology
American Journal of Microbiological Research
Biomedical Science and Engineering

We are pleased to announce that submissions are now being accepted for peer review for all the journals across all our subject areas in SciEP.

Please submit your manuscript via our online submission system:
http://www.sciepub.com/author/signin

To unsubscribe from our mailing list, please click on the following link: unsubscribe

I am looking forward to hearing from you.

Kind regards,

David Rain
Email:join@sciepub.com
Science and Education Publishing (http://www.sciepub.com)

Deaminated Gliadin Peptide Antibody in the Diagnosis of Celiac Disease

You Yi Hong

Gastroenterology Department, Galway University Hospitals, Republic of Ireland

Abstract:

Keywords:

Received May 02, 2015; Revised May 20, 2015; Accepted June 02, 2015

Citation: You Yi Hong, Deaminated Gliadin Peptide Antibody in the Diagnosis of Celiac Disease. International Journal of Celiac Disease, 3 (2). 56-57. January 2015. doi:10.12691/ijcd-3-2-8

Celiac Disease (CD) is an immune-mediated gluten-sensitive enteropathy, characterised by intolerance to dietary gluten. [1] Indigestion of gluten containing food, among individual susceptible to CD will lead to immune-mediated inflammatory cascade primarily in small bowel mucosa, leading to intestinal villous atrophy. The worldwide prevalence of CD is around 1%, with slightly higher prevalence in certain part of the world. [2,3] Genetic predisposition plays a vital role in CD, with both the HLA-DQ2 and HLA-DQ8 genes are strongly associated with it. About 95% of patients with CD express HLA-DQ2, and the rest of them are usually HLA-DQ8 positive. [1,3,4,5] Environmental exposure of gluten in the genetic susceptible individual is the key event in the development of CD. Gluten Free Diet (GFD) is the only proven effective treatment for CD as there is no other proven alternative to prevent intestinal mucosal damage due to gluten exposure, among population with CD.

The gold standard for diagnosis of CD is the histopathological analysis of small intestinal biopsy (usually second part of duodenum). [1] A few serological blood tests like anti Gliadin antibody (AGA), Endomysial antibody (EMA), tissue Transglutaminase antibody (tTG), and more recently Deaminated Gliadin Peptide (DGP) antibody are used for screening, diagnosis and follow up for patients with CD. [6] Celiac serological test is very useful diagnostic tool in the diagnosing process of CD. Serological screening tests can be used to identify patients at risk of CD to proceed with diagnostic gastroscopy and small intestinal biopsy. Apart from that, celiac serological tests can be utilized in monitoring the response and compliance to GFD [7,8].

AGA was widely used previously but the current utilization of AGA is limited due to its low sensitivity and specificity.[9] While both IgA anti-tTG and EMA would be the tests of choice in current clinical practice, DGP antibody test has been shown to have very good sensitivity and specificity.[10] In fact, several studies have demonstrated that IgG DGP antibody has a higher specificity and sensitivity than IgG tTG antibody in both adults and paediatric population population [11,12].

The low sensitivity and specificity of AGA has been attributed to the fact that the Gliadin used in the test was not deaminated. [13] DGP, which has been introduced as part of serological work-up in CD, enhances the antibody response by deamidation of gliadin peptides. Deamidation of gliadin plays a vital stage in the pathogenesis of CD. As gliadin entering the small intestinal mucosa is deamidated (the blinding of gliadin to HLA-DQ2 or DQ8 is strongly enhanced by deamidation), the modified antigens stimulate B-lymphocytes to create antibodies against the deamidated peptides. [10,13,14] The antibodies in subjects with CD will identify the deamidated gliadin peptides better than gliadin peptides. [13] Rashtak et al has demonstrated DGP Antibody is a better test for CD comparing to the AGA, with non-inferior performance comparing to IgA tTG antibody [6].

A meta-analysis by Lewis et al concluded that IgA DGP antibody is less sensitive comparing to IgA tTG antibody (88% vs. 93%). [14] While the study shows that the specificity of both IgA DGP antibody and IgA tTG antibody are high (>94% and >96% respectively), the study found that IgG DGP antibody is less sensitive, but more specific comparing to IgA-DGP antibody. However, there was a number of methodological weaknesses in both the primary studies included and the meta-analysis itself. [14] The trade off between sensitivity and specificity is always the centre of concern in a diagnostic test. [15] The ideal medical diagnostic test of 100% sensitive and 100% specific is virtually non-existence. The combination of IgG DGP antibody and IgA tTG antibody offers the best sensitivity and specificity in diagnosing CD. [1,9,14,16] This combination will increase the sensitivity in detecting CD, without lowering its specificity.

Around 2% of patients with CD are IgA deficient, and population with IgA deficiency will have higher risk of CD. [17] IgA tTG antibody alone will miss the case of CD with IgA deficiency, with false negative result. In such a scenario, IgG DGP or IgG tTG antibody can be very useful as part of the diagnosis cascade for CD.

Currently, there is 1 commercially available point of care test (POCT) which is based on DGP antibody. The DGP based POCT (Simtomax) available will detect both IgA and IgG DGP antibodies. [18] With its high negative predictive value of more than 99.1%, it was originally developed for screening of CD. [18] DGP based POCT (Simtomax) had a greater sensitivity than the other POCTs (Biocard and Coeliac Quick Test based on tTG antibodies) that were tested in patients referred with a positive EMA. [19] Mooney et al has demonstrated that the DCP based POCT has comparable diagnostic accuracy to standard serological markers when used in an endoscopic setting. They have validated a clinically feasible diagnostic algorithm, based on DGP-based POCT, for identifying patients with CD in endoscopy setting. [19] DGP- based POCT is also shown to have a great potential be an instrument used to monitor compliance to GFD among patients with known CD. [7,8] As the sensitivity and negative predictive value of DGP-based POCT in predicting compliance to GFD were high, in routine Celiac clinic settling, the immediate availability of result (in detecting gluten ingestion) will allow for an on-the-spot management decision [7].

In conclusion, DGP antibody has proven to be an importance celiac serological test, along with more conventional tTG antibody and EMA, as part of the investigation for CD. DGP antibody also has the potential to be used as the individual celiac serological test or it can be used as a combination to other celiac serological tests. The combination of IgG DGP antibody and IgA tTG antibody provide the best diagnostic accuracy for CD. The availability of DGP-based POCT is particularly useful due to its instantaneous result, and its ability to be utilised in primary care settling, celiac clinic or even the endoscopy settling.

References

[1]  
Ludvigsson JF, Bai JC, Biagi F, Card TR, Ciacci C, Ciclitira PJ, Green PH, Hadjivassiliou M, Holdoway A, van Heel DA, Kaukinen K, Leffler DA, Leonard JN, Lundin KE, McGough N, Davidson M, Murray JA, Swift GL, Walker MM, Zingone F, Sanders DS; BSG Coeliac Disease Guidelines Development Group; British Society of Gastroenterology. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut 2014;63:1210-1228.

[2]   | Green PH, Jabri B, Coeliac disease. Lancet 2003; 362: 383-391.
[3]   | Green PH, Cellier C, Celiac Disease. N Engl J Med 2007; 357: 1731-1743.
[4]   | Sollid LM, Lie BA, Celiac disease genetics: current concepts and practical applications. Clinical Gastroenterology and Hepatology, 2005; 3: 843-851.
[5]   | Setty M, Hormaza L, Guandalini S, Celiac Disease: risk assessement, diagnosis and monitoring. Mol Diagn Ther 2008; 12: 289-298.
[6]   | Rashtak S, Ettore MW, Homburger HA, Murray JA., Comparative Usefulness of Deamidated Gliadin Antibodies in the Diagnosis of Celiac Disease. Clin Gastroenterol Hepatol 2008;6:426-432.
[7]   | Hong YY, K.C., Byrnes V, Anti-Deamidated Gliadin Peptides Rapid Test (Simtomax) as a Simple and Quick Measure of Compliance to Gluten Free Diet in Patients with Celiac Disease, in 15th International Celiac Disease Symposium September 2013: Chicago.
[8]   | Monzani A, Rapa A, Fonio P, Tognato E, Panigati L, Oderda G, Use of Deamidated Gliadin Peptide Antibodies to Monitor Diet Compliance in Childhood Celiac Disease. J Pediatr Gastroenterol Nutr 2011; 53: 55-60.
[9]   | Kaukinen K, Collin P, Laurila K, Kaartinen T, Partanen J, Mäki M., Resurrection of gliadin antibodies in coeliac disease. Deamidated gliadin peptide antibody test provides additional diagnostic benefit. Scand J Gastroenterol 2007; 42: 1428-1433.

[10]  
Ankelo M, Kleimola V, Simell S, Simell O, Knip M, Jokisalo E, Tarkia M, Westerlund A, He Q, Viander M, Ilonen J, Hinkkanen AE, Antibody responses to deamidated gliadin peptide show high specificity and parallel antibodies to tissue transglutaminase in developing coeliac disease. Clin Exp Immunol 2007; 150: 285-293.

[11]   | Liu E, Li M, Emery L, Taki I, Barriga K, Tiberti C, Eisenbarth GS, Rewers MJ, Hoffenberg EJ, Natural history of antibodies to deamidated gliadin peptides and transglutaminase in early childhood celiac disease. J Pediatr Gastroenterol Nutr 2007; 45: 293-300.
[12]   | Schwertz E, Kahlenberg F, Sack U, Richter T, Stern M, Conrad K, Zimmer KP, Mothes T, Serologic assay based on gliadin-related nonapeptides as a highly sensitive and specific diagnostic aid in celiac disease. Clin Chem 2004; 50: 2370-2375.
[13]   | Mothes T, Deamidated Gliadin Peptides as Targets for Celiac Disease Specific Antibodies. Adv Clin Chem 2007;44:35–63.
[14]   | Lewis NR, Scott BB, Meta-analysis: deamidated gliadin peptide antibody and tissue transglutaminase antibody compared as screening tests for coeliac disease. Aliment Pharmacol Ther 2010; 31: 73-81.
[15]   | Stephen B.Hulley, S.R.C., Warren S.Browner, Deborah G.Grady, Thomas B.Newman, Designing Clinical Research. 2013: Lippincott Williams & Wilkins.
[16]   | Volta U, Villanacci V, Celiac Disease: Diagnostic Criteria in Progress. Cell Mol Immunol 2011; 8: 96-102.
[17]   | Chow MA, Lebwohl B, Reilly NR, Green PH., Immunoglobulin A deficiency in celiac disease. J Clin Gastroenterol 2012;46:850-854.
[18]   | Simtomax: Accurate and rapid detection of Celiac Disease. 2015 [cited 2015; Available from: http://www.augurix.com/wp-content/uploads/2014/05/Augurix-sheetSimtomaxAug2013_small.pdf.
[19]   | Mooney PD, Wong SH, Johnston AJ, Kurien M, Avgerinos A, Sanders DS, Increased Detection of Celiac Disease With Measurement of Deamidated Gliadin Peptide Antibody Before Endoscopy. Clin Gastroenterol Hepatol 2015.